Information Provided By: 
Fly News Breaks for June 7, 2017
JAZZ
Jun 7, 2017 | 07:36 EDT
JPMorgan analyst Jessica Fye believes full results from the Phase III JZP-110 narcolepsy and obstructive sleep apnea studies established a "compelling clinical profile" and beat investor expectations. JZP-110 represents a long-term growth driver outside of Xyrem, Fye tells investors in a research note. She believes the current valuation does not fully the double-digit growth she expects Jazz to generate over the next several years. The analyst reiterates an Overweight rating on the shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
